ADC Therapeutics SA
NYSE:ADCT
1.96 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Omzet
| 69.558 | 209.908 | 33.917 | 0 | 2.34 | 1.14 | 1.803 |
Kosten van de omzet
| 2.529 | 4.579 | 1.393 | 1.972 | 107.537 | 118.086 | 85.53 |
Brutowinst
| 67.029 | 205.329 | 32.524 | -1.972 | -105.197 | -116.946 | -83.727 |
Brutowinstmarge
| 0.964 | 0.978 | 0.959 | 0 | -44.956 | -102.584 | -46.438 |
Onderzoek- en ontwikkelingskosten
| 127.127 | 187.898 | 158.002 | 142.032 | 107.537 | 118.313 | 85.53 |
Algemene en administratieve kosten
| 48.424 | 141.058 | 71.462 | 77.231 | 13.814 | 8.602 | 7.806 |
Verkoop- en marketingkosten
| 57.464 | 69.052 | 64.78 | 22.101 | 0 | 0 | 0 |
Verkoop-, algemene en administratieve kosten
| 105.888 | 141.058 | 136.242 | 77.231 | 13.814 | 8.602 | 7.806 |
Overige kosten
| 0 | 14.578 | 28.489 | -46.398 | 0.388 | 0.166 | 0.137 |
Bedrijfskosten
| 233.015 | 328.956 | 294.244 | 219.263 | 121.739 | 127.081 | 93.473 |
Bedrijfsresultaat
| -165.986 | -123.627 | -261.72 | -219.263 | -119.399 | -125.941 | -91.67 |
Bedrijfsresultaat ratio
| -2.386 | -0.589 | -7.716 | 0 | -51.025 | -110.475 | -50.843 |
Totaal overige inkomsten en kosten netto
| -29.433 | -33.557 | 10.215 | -26.7 | 3.497 | 3.069 | 1.856 |
Inkomen voor belasting
| -195.419 | -154.661 | -251.505 | -245.963 | -115.902 | -122.872 | -89.814 |
Inkomen voor belasting ratio
| -2.809 | -0.737 | -7.415 | 0 | -49.531 | -107.782 | -49.814 |
Belastingkosten
| 39.106 | 1.139 | -21.479 | 0.327 | 0.582 | 0.224 | 0.048 |
Nettowinst
| -240.053 | -155.8 | -230.026 | -246.29 | -116.484 | -123.096 | -89.862 |
Nettowinstmarge
| -3.451 | -0.742 | -6.782 | 0 | -49.779 | -107.979 | -49.84 |
WPA (Winst Per Aandeel)
| -2.94 | -1.99 | -3 | -3.77 | -1.74 | -2.29 | -1.53 |
Verwaterde WPA
| -2.94 | -1.99 | -3 | -3.77 | -1.74 | -2.29 | -1.53 |
EBITDA
| -146.762 | -108.055 | -223.715 | -219.263 | -114.1 | -122.359 | -91.329 |
EBITDA ratio
| -2.11 | -0.471 | -6.875 | 0 | -48.652 | -110.012 | -51.111 |